BDI Announces Agreement With Apotex to Distribute HepaGam B

Blood Diagnostics, Inc. (BDI), one of the leading distributors of recombinant and plasma-derived pharmaceutical products, today announced immediate availability of HepaGam B, the first intravenous hepatitis B immune globulin approved by the FDA. Because the products can be administered intravenously, the HepaGam B enables healthcare providers to treat HBsAg-postive liver transplant patients prophylactically to prevent hepatitis B recurrence following transplantation.

“Our customers rely on BDI to offer innovative products and therapies as they become available,” said Richard Gaton, President of BDI. “We are excited to be able to complement our hyper-immune product line with the addition of HepaGam B to our product portfolio.”

BDI offers an extensive line of hyper-immune products, including immune globulins administered for the post-exposure prophylactic treatment of Hepatitis A, Hepatitis B, Rabies, Rh Sensitization, and Tetanus.

HepaGam B is a sterilized solution of purified gamma globulin (IgG) fraction derived from human plasma containing antibodies to hepatitis B surface antigen. It is manufactured by Cangene and distributed by Apotex. The product is manufactured from human plasma obtained from suitable healthy donors who have been vaccinated with a recombinant hepatitis B vaccine. The plasma from these donors contains high levels of anti-hepatitis B antibodies, which are purified to make HepaGam B.

About BDI

BDI is an independent, wholesale distributor of recombinant and plasma-derived pharmaceuticals. For more than a decade, the company has built an excellent reputation with its customers as a reliable source for products and service. Since 1995 BDI has represented the complete line of products derived from human plasma, as well as products derived from recombinant technology, to medical facilities throughout the United States. BDI specializes in Albumin (Human) USP, intravenous immune globulin (IVIG or IGIV), coagulation factors VIIa, VIII and IX, as well as hyper-immunes and injectable products (vaccine). BDI is authorized as a distributor for all of the major plasma derivative manufacturers, is fully insured and fulfills the licensing requirements in all 50 states. With distribution centers located on both coasts, BDI offers prompt shipping as well as emergency delivery service.

BDI was founded on the principles of professional integrity, customer service and commitment to the plasma industry. Emergency 24 / 7 availability, unparalleled customer service, and extensive product knowledge define its customer-centric approach to serving the nation’s healthcare community. The company serves as a free source for reference material and market data, offering healthcare providers the latest information on products, supply shortages and other industry events. BDI’s promotional literature and web site serve as open-access educational resources, contributing to the promotion of the industry and the education of both the healthcare community and general populace.

 Contact: John Noel 803-732-1018 Contact via http://www.marketwire.com/mw/emailprcntct?id=B220FA064D777F3D  

SOURCE: Blood Diagnostics, Inc.